This study was designed to test the hypothesis that inhalation of nitric oxide by lambs delivered prematurely would result in increased systemic arterial blood oxygen tension and decreased pulmonary vascular resistance. Eleven premature fetal lambs were delivered by cesarean section at 126-127 d gestation. One hundred min after the onset of ventilation, nitric oxide gas was added to the lambs' breathing mixture. The animals were exposed in random order to 5 pprn for 10 min, 20 pprn for 10 min, and 20 pprn for 20 min. Each treatment period was preceded by and followed by a 10-min washout period. When compared with the washout (control) periods, all three treatment periods resulted in an improvement in both the systemic arterial blood oxygen tension and the physiologic intrapulmonary shunt. Inhalation of nitric oxide also resulted in a selective decrease in pulmonary arterial blood pressure. Comparisons between the different treatment groups revealed a further improvement in blood oxygenation and pulmonary hemodynamics when using the higher concentration of nitric oxide. Interestingly, the rise in arterial blood oxygenation continued after inhaling 20 pprn nitric oxide for more than 10 min. (Pediatr Res 37: [35][36][37][38][39][40] 1995) Abbreviations QsIQt, physiologic intrapulmonary shunt PAP, mean pulmonary arterial pressure ppm, parts per million RDS, respiratory distress syndrome SAP, mean systemic arterial pressure LAP, left atrial pressure RAP, right atrial pressure Qp, pulmonary blood flow PVR, pulmonary vascular resistance Pao,, arterial oxygen partial pressure Nitric oxide, an inorganic gas formed by combustion processes, has been recognized for many years as an industrial pollutant. In fact, cigarette smoke contains nitric oxide gas in concentrations up to 1000 pprn (1). In both dogs (2, 3) and humans (4-6), inhalation of concentrations of more than 15 000 pprn rapidly causes a fatal condition involving severe alveolar edema, methemoglobinemia, and hypoxemia. Ironically, inhalation of concentrations less than 100 pprn has been used in an attempt to facilitate the management of several cardiopulmonary diseases such as persistent pulmonary hypertension of the newborn (7,8), primary pulmonary hypertension (9, lo), and adult RDS (11).Treatment of pulmonary hypertension with i.v. administered vasodilator agents has been limited because of the inability to localize the effects of these drugs to the pulmonary circulation. Nitric oxide gas seems to be an ideal drug to obviate this problem. Experience in animals (12-16) and humans (9,17) Received March 18, 1994; accepted June 5, 1994. Supported by grants from the American Heart Association, Florida Affiliate (AHA Awards 93CRFl6, 92Fl2, and 91GIAn16), and the National Institute of Health Grant HL10834.suggests that inhaled nitric oxide can cause a decrease in PVR without causing significant systemic hypotension. The mechanisms of this selective pulmonary vasodilation are not entirely understood; however, the short half-life of nitric oxide (18,19) and its rapi...